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ABSTRACT 
INTRODUCTION 
Children hospitalized with culture-confirmed pulmonary tuberculosis (PTB) frequently 
present with acute symptoms, possibly because underlying PTB may predispose to 
superimposed bacterial pneumonia. Immunization of children with pneumococcal 
conjugate vaccine (PCV) could protect against such superimposed bacterial pneumonia 
and reduce the incidence of PTB hospitalization.   
 
OBJECTIVE 
We studied the temporal association of childhood immunization with pneumococcal 
conjugate vaccine on the incidence of hospitalization for culture-confirmed PTB in 
children. 
 
METHODS 
A retrospective study on the incidence of hospitalization for culture-confirmed childhood 
PTB at Chris Hani Baragwanath Academic Hospital was undertaken from 2005 to 2012. 
This included a pre-PCV era (2005-2008) and a PCV era (2011-2012).  
 
RESULTS 
Overall, there was a 69.2% (95% CI: 62.8-74.6%) decline in the incidence of 
hospitalization for culture-confirmed PTB when comparing the PCV and pre-PCV-eras, 
with the decline in HIV-uninfected children only significant in the 3-11 month age 
category and the decline in HIV-infected significant across all age categories. There was 
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a trend for reduced pneumococcal bacteraemia in the PCV era compared to the pre-
PCV era, with the odds of having a blood culture positive for pneumococcus being 1.91-
fold (95% CI, 0.26-84.56) greater in the Pre-PCV era. 
 
CONCLUSION 
There has been a significant decline in culture-confirmed PTB hospitalization in children 
comparing the pre-PCV to the PCV-era. However, the incidence of culture-confirmed 
PTB prior to the introduction of PCV had been reduced to low levels due to antiretroviral 
therapy. This confounder together with the retrospective ecological study design and 
other several possible confounders limited any robust estimate as to whether there was 
a temporal association between PCV immunization and incidence of culture-confirmed 
PTB hospitalization in our study setting.  
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1.0 Introduction 
Pneumonia is a major cause of childhood morbidity and mortality worldwide, particularly 
in low-income countries (1). Streptococcus pneumoniae (the pneumococcus) and 
Mycobacterium tuberculosis (MTB) have been implicated in the aetiology of childhood 
pneumonia in sub-Saharan Africa (2-4). The burden of pneumococcal disease and 
tuberculosis (TB) has increased as a result of the human immunodeficiency virus (HIV) 
epidemic. The overall burden of severe invasive pneumococcal disease (IPD) and 
pulmonary tuberculosis (PTB) is significantly greater in HIV-infected compared to HIV-
uninfected children (5, 6). Antiretroviral therapy (ART) programs have reduced the 
incidence of PTB and IPD in HIV-infected children (7-10). 
 
Challenges in directly delineating the role of bacteria (including pneumococcus) and 
MTB as aetiological agents of pneumonia, include the lack of sensitive diagnostic tools 
in the absence of direct lung sampling (11-14). Gastric washing or induced sputum 
culture for MTB is only positive in 15-30% of PTB cases (15), whilst blood cultures 
positive for culture of pneumococcus occurs in only approximately 2.6% and 18.8% of 
HIV-uninfected and -infected children with pneumococcal pneumonia, respectively (16). 
 
Nevertheless, S. pneumoniae is recognized as the leading bacterial cause of 
community-acquired pneumonia in children (17). At least 94 pneumococcal serotypes 
have been identified, distinguished based on antigenic differences in the polysaccharide 
cell wall, an important virulence component of the bacterium. Thirteen serotypes, 
however, cause the majority (70-75%) of IPD in children (18). Pneumococcal conjugate 
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vaccine (PCV) was introduced in the USA in 2000, and subsequently recommended by 
the World Health Organization (WHO) for introduction into public immunization 
programs in low- and middle-income countries (18).  
 
The introduction of heptavalent PCV (PCV7) has resulted in a marked reduction in rates 
of IPD. The resultant impact on IPD caused by vaccine serotypes has been consistent 
across countries including South Africa, with a reduced incidence ranging from 79% to 
100% (19, 20). In a South African study the incidence of invasive pneumococcal 
disease caused by vaccine serotypes in children younger than 2 years of age declined 
by 89% (95% CI, −92 to −86%) (20). Furthermore, PCV has resulted in a reduction of 
hospitalization from all-cause radiologically confirmed pneumonia as defined by WHO 
interpretation (21, 22). 
 
The burden of TB in South Africa is among the highest globally (23, 24). Hospitalization 
for  PTB in children frequently presents as an acute illness in South Africa, with 43%-
77% of hospitalized children subsequently confirmed as having culture confirmed PTB 
presenting with cough of <7-10 days duration (6, 25). This acute presentation of PTB 
may be related to superimposed infections precipitating as acute illness in children with 
underlying primary PTB. This was alluded to in a PCV vaccine-probe study, which 
demonstrated a 43% (95% confidence interval [CI], 10-65%) reduction in hospitalization 
for culture-confirmed PTB in PCV-vaccinated compared to PCV-unvaccinated children 
(25). 
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The likely role of bacterial co-infection precipitating hospitalization in children with 
underlying PTB is further supported by the observation that approximately 50% of 
children hospitalized with culture-confirmed PTB in our setting, where >70% of such 
cases present with cough duration of <7 days, are discharged clinically well following 
empiric treatment for bacterial pneumonia and without initiation of anti-TB drugs (25). 
The latter is largely due to the low threshold for investigating of TB in a high burden-
setting such as ours, coupled with the lag of 4-6 weeks before MTB culture results 
become available (25, 26). Similar acute clinical symptoms in hospitalized children 
subsequently diagnosed to have culture-confirmed TB have also been observed 
elsewhere in South Africa (6, 27).  
 
There are a limited number of studies which have directly documented the prevalence 
of co-infections with bacteria or respiratory viruses in individuals with PTB. Previously in 
Soweto during the mid-1990s, 10% of children hospitalized with culture-confirmed PTB 
had concurrent bacteraemia (4). In addition, two descriptive studies among South 
African adults also identified S. pneumoniae and MTB co-infections among HIV-infected 
individuals presenting with community acquired pneumonia and pericarditis (28, 29).  
 
It is postulated that several factors in TB disease contribute to the increased risk of 
bacterial infections. IL-4 in advanced TB cases down-regulates the protective Th1 
immune responses (30). The assembly of defensins which are an important factor of the 
innate immune response against microorganisms have been found to be reduced with 
progression of TB disease (31). Gamma interferon has also been found to induce 
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erosion of pre-existing CD8+ T cell memory to intracellular pathogens during TB 
infection (31). These factors cause immune dysfunction in patients with underlying TB, 
which could predispose them to bacterial infections (25). 
The aim of this study was to determine the temporal association of infant PCV 
immunization on the incidence of hospitalization for culture-confirmed PTB in HIV-
infected and HIV-uninfected children. 
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1.1 Hypothesis and objectives 
Null Hypothesis 
Introduction of PCV into the South African pubic immunization program is not 
associated with a reduction in the incidence of hospitalization for culture-confirmed PTB 
in children. 
 
Study design: 
A retrospective, ecological study analyzed the incidence for hospitalization of culture-
confirmed PTB in children from Soweto, South Africa, between 2005 and 2012. 
 
Primary objective:  
To determine the temporal association of infant PCV immunization on the incidence of 
hospitalization for culture-confirmed PTB in HIV-infected and HIV-uninfected 
hospitalized children in Soweto. 
 
Secondary objective:  
To determine the proportion of children with culture-confirmed PTB who had concurrent 
bacteraemia.  
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2.0 Study design and methods 
2.1 Study population and setting 
The study was undertaken in Soweto, which spreads over an area of 108 square 
kilometers. Chris Hani Baragwanath Academic Hospital (CHBAH) is a 
secondary/tertiary level hospital situated in this low-middle income South African 
township, near Johannesburg in Gauteng Province. Chris Hani Baragwanath Academic 
Hospital has 3,200 beds, including 408 for children. The hospital serves a population of 
approximately 1.25 million people including 128,000 children under-5 years of age (32, 
33). 
 
The prevalence of HIV in Gauteng has remained stable at 16-17% in adults and 2-3% in 
children between 2005 and 2012 (32). The roll-out of ART for the treatment of HIV 
infection was implemented by the South African government in April 2004 (34). Also, the 
vertical transmission of HIV from mother-to-child declined to <2.5% from 2010 onward 
with the currently used ART-regimens in pregnant women (35). In Gauteng, the 
percentage of children with Acquired Immunodeficiency Syndrome (AIDS) that were on 
ART increased from 40.6% in 2005 to 96.1% in 2012 (32) (Appendix 1, page 39). 
Recent studies at CHBAH showed that increased uptake of ART among HIV-infected 
children in Soweto was associated with decline in the incidence of hospitalization for 
culture-confirmed PTB (70.6%) and IPD (50.8%), which occurred prior to PCV 
introduction, whereas lesser changes for PTB (41.3%) and no significant changes for 
IPD were observed among the HIV-uninfected children (8, 10). 
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Heptavalent PCV, which includes serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, was 
introduced into the South Africa public immunization program in April 2009. The PCV7 
was replaced by 13-valent PCV (PCV13), which includes serotypes 1, 3, 5, 6A, 7F and 
19A (in addition to those incorporated into PCV7), in May 2011. The PCV7 and PCV13 
vaccines provided potential coverage against 67% and 88%, respectively, of serotypes 
associated with IPD in South African children in the absence of PCV-vaccination (18).  
 
The PCV schedule in South Africa includes two primary doses at 6 and 14 weeks and a 
third (booster) dose at 9 months of age. This schedule is more immunogenic following 
the third dose compared to the 6, 10 and 14 week three-dose primary schedule 
previously studied in the same population (36). No catch-up campaign of older children 
was undertaken at the time of the introduction of PCV7 into the public immunization 
program, whilst a limited catch-up campaign targeting high-risk children 18 to 36 months 
of age was undertaken at the time of transitioning to PCV13 (37). Whilst the coverage of 
three doses of PCV in South African infants was estimated to be 10% in 2009, this 
steadily increased to 64% and 89% by 2010 and 2011, respectively (38). In Gauteng, 
coverage with the third-dose was 86% in 2010 and approximately 100% in 2011 and 
2012 (39).  
 
Children presenting with symptoms of severe pneumonia or lower respiratory tract 
infections (LRTI) as per WHO case definitions (40) are routinely admitted at CHBAH 
which, at the time of this study was the only public sector health facility with in-patient 
paediatric beds in Soweto. These children usually have a blood culture test undertaken 
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at admission and chest radiographs. Children admitted with acute respiratory tract 
infections are also investigated for PTB at the discretion of attending physicians, who 
because of the high burden of TB in the setting have a low threshold for investigating for 
PTB. Gastric aspirates and/or induced sputum are collected on 2-3 separate occasions 
and tested for MTB by microscopy and/or liquid mycobacterial culture. Gene-Xpert 
testing became available at CHBAH in 2012, but was not routinely used in the TB 
diagnostic work-up of children at the facility during the study period. Ampicillin was the 
first line antibiotic for the treatment of childhood community-acquired pneumonia at 
CHBAH at the time of this study, with the addition of gentamicin (for Gram negative 
cover) in immunocompromised and malnourished children.  
 
2.2 Study procedures  
Data on children hospitalized for culture-confirmed PTB from 2005 to 2009 had been 
previously analyzed in a study that interrogated the effect which the upscaling of the 
ART program in HIV-infected children had on the incidence of PTB hospitalization (8). 
The method used for determining the culture-confirmed PTB cases from 2005 to 2009 
has been described (8). Patients aged 0-3 months were excluded from the previous 
analysis as they were considered to represent cases of congenital TB (41). 
 
This study expanded on the previous study, using the same methodologies for 
identifying cases of culture-confirmed PTB in children less than 15 years of age 
hospitalized to the general paediatric wards at CHBAH from 2010 to 2012. Briefly, 
cases of culture-confirmed PTB were extracted from the National Health Laboratory 
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Service (NHLS) database, and cross-referenced against an electronic database of all 
admissions to the general paediatric wards at CHBAH. This electronic database is 
maintained by the Respiratory and Meningeal Pathogens Research Unit (RMPRU) 
based at CHBAH. Hospital records of these patients were retrieved and information 
extracted onto a standardized data collection form (Appendix 2, page 40). In cases 
where the hospital records were not retrievable, available clinical information was 
extracted from a discharge summary database. The hospital registration system 
(MEDICOM) and hospital admission registries were also checked for confirmation of 
hospitalization and outcome status. 
 
Admission blood results (usually full blood count and blood culture) were retrieved from 
the NHLS database. HIV status, CD4+ lymphocyte counts, HIV viral load and duration 
of ART were determined by review of the NHLS and electronic paediatric databases. 
Anthropometry measurements were extracted from the paediatric database and weight 
for age z-scores in children less than 10 years were calculated as per the WHO child 
growth standards using WHO AnthroPlus version 1.0.4 (42). 
 
The standard of care for diagnosis of HIV positivity at CHBAH include confirmation of a 
positive initial serologic result by qualitative HIV PCR in children under 18 months of 
age or a positive HIV ELISA test in children over 18 months of age, or a detectable HIV 
viral load if qualitative HIV PCR or serologic test results were unavailable. Infants with a 
positive HIV exposure history are tested with HIV PCR, and a positive result is 
confirmed with an HIV viral load test. The most recent CD4+ counts within three months 
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of the TB admission episode were included in the analysis, to attribute immunological 
status in the HIV-infected children. WHO levels of immune suppression based on CD4+ 
percentage/count categorization were used to stage the extent of immunosuppression 
(43) (Appendix 3, page 41).  
 
Children were included in the analysis if their respiratory samples (gastric aspirates, 
induced sputum, expectorated sputum, tracheal aspirates or broncho-alveolar lavage 
secretions) were positive for MTB within one month of hospitalization for an episode of 
severe pneumonia, irrespective of duration of symptoms, and had not been initiated on 
TB treatment for more than two weeks prior to the admission. Excluded from the 
analysis were children 0-3 months and those older than 15 years of age. 
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2.3 Statistical analysis  
The estimated incidence rates for culture-confirmed PTB were calculated and stratified 
by age group (3-11 months, 12-23 months, 24-59 months and 60-179 months) and HIV 
status to yield annual PTB incidence rates over an eight year period. In addition, the 
estimated incidence of culture-confirmed PTB was calculated in three time periods, 
designated the Pre-PCV era between 2005-2008 (i.e. Period 1), Transitional-PCV era 
between  2009-2010 (i.e. Period 2) and Established-PCV era between 2011-2012 (i.e. 
Period 3) based on the coverage for the third dose of PCV . As the coverage in 2009 
was only 10% and 64% by 2010, these years were considered as transitional years for 
PCV introduction. Incidence rate ratios (IRR) were calculated to compare the burden of 
PTB in HIV-infected and HIV-uninfected children for Period 1 and Period 3.  
 
The numerators for the incidence calculations were the number of culture-confirmed 
PTB cases hospitalized during each year/period and the denominators were based on 
mid-year population estimates from the Gauteng Department of Health and Social 
Development for region D, Soweto (Johannesburg), as per Statistics South Africa report 
(44). HIV prevalence in the study population was derived from the AIDS and 
Demographic models 2008 as per the Actuarial Society of South Africa (32) (Appendix 
4, page 42). 
 
The X2 test (or Fisher’s exact test, where appropriate) was used for the comparison of 
proportions for categorical variables. Student’s t-test was used for the comparison of 
means for normally-distributed continuous variables and the Wilcoxon sign-rank test 
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was used to compare medians of skewed continuous variables. 95% confidence 
intervals (CIs) are reported, with p-values <0.05 considered as statistically significant.  
 
The average of the previous, index and following month incidence rates were plotted 
against time to highlight overall trends, as was done in a previous study (8). This is also 
known as the 3-term moving average. It is used to smooth out short-term disparities 
when examining time-series data. For example, the 3-term moving average in June 
2010 would be the average of the incidence rates in May 2010, June 2010 and July 
2010.  
 
Demographic data and estimates of incidence and IRR were analyzed using STATA 
version 12.0 (StataCorp, College Station, Texas, USA) and Epi Info version 3.5.1 (CDC, 
Atlanta, USA). The 3-term moving average was analyzed using R version 2.13 
(Foundation for Statistical Development, Vienna, Austria). 
 
2.4 Ethical Considerations 
Permissions were obtained from the Human Research Ethics Committee (Medical) of 
the University of the Witwatersrand and CHBAH Medical Advisory Committee to 
conduct the study (Appendix 5, page 43). Permissions were also obtained from the 
Paediatrics Department of the University of the Witwatersrand and from the NHLS for 
the use of laboratory data. Dr Ziyaad Dangor collaborated on (and co-supervised) this 
study and provided data for the 2005 to 2009 culture-confirmed PTB cohort. There was 
no need for informed consent because this was a retrospective study.
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RESULTS 
3.1 Identification of children hospitalized with culture-confirmed PTB (Figure 1) 
In Period 1 (2005-2008), 792 children were hospitalized for culture-confirmed TB, 667 
(84%) of which had PTB. Reasons for exclusion of cases between 2005 and 2008 
included 93 children aged 0-3 months (potential congenital TB cases) and 32 children 
where culture-confirmed TB were from extrapulmonary sites (specimens other than 
gastric washings, sputum or broncho-alveolar lavage). 
 
Period 2 included cases from 2009 and 2010, during which 199 children were identified 
with culture-confirmed TB; of whom 157 (78.9%) were hospitalized with PTB.  Reasons 
for exclusion of cases in Period 2 included 17 children aged 0-3 months, 15 children 
with culture-confirmed TB from extrapulmonary sites, and 10 children who were 
diagnosed with PTB but not hospitalized. 
 
Between 2011 and 2012 (Period 3), 174 children were hospitalized with culture-
confirmed TB, of whom 48 were excluded, including 23 aged 0-3 months, MTB being 
cultured from a non-respiratory specimen in 22 children, two children never having been 
hospitalized and one child in whom TB treatment was initiated >2 weeks prior to 
admission for pneumonia. Therefore 126 children between the ages of 3 months and 15 
years were hospitalized with culture-confirmed PTB in Period 3. 
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Period 1: 2005-2008 Period 2: 2009-2010 Period 3: 2011-2012
792 patients hospitalized with 
culture-confirmed TB
93 0-3 months 32 EPTB
2009: 100 patients hospitalized 
with culture-confirmed TB
2010: 99 patients with culture-
confirmed TB extracted from  
NHLS database (from paediatric 
wards, sleepover wards, 
outpatient department and 
paediatric HIV clinic)
17 0-3 months 15 EPTB 10 
sleepovers
174 patients with culture-
confirmed TB extracted from  
NHLS database (from 
paediatric wards, sleepover 
wards, outpatient department 
and paediatric HIV clinic)
23 0-3 months 22 EPTB 2 
sleepovers
1 already on 
TB treatment
667 patients hospitalized 
with culture-confirmed PTB
157 patients hospitalized 
with culture-confirmed PTB
126 patients hospitalized 
with culture-confirmed PTB
950 patients hospitalized for culture-
confirmed PTB
 
Figure 1: Flow diagram of children hospitalized with culture-confirmed PTB 
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3.2 Demographic information of Culture-confirmed PTB cases (Table 1) 
Overall, 514 (54%) of the 950 culture-confirmed PTB cases were HIV-infected, 345 
(36%) were HIV-uninfected and the HIV infection status was unknown in 91 (10%). The 
number of children with unknown HIV status and the number of HIV infected cases 
decreased over the eight year study period (Table 1). 
 
The median age of culture-confirmed PTB cases was 25 months (Interquartile range 
[IQR], 9 to 85 months) across the eight year study period. The overall median age for 
culture-confirmed TB cases initially increased from 19 months (IQR, 8 to 72 months) in 
2005 to 59 months (IQR, 15 to 123 months) in 2010 (p<0.001); including from 21 
months (IQR, 8 to 82 months) to 92 months (IQR, 35 to 137 months) in HIV-infected 
children (p<0.001) in the respective periods. The median age of culture-confirmed PTB 
(all children, regardless of HIV status) subsequently decreased in 2012 to 24 months 
(IQR, 10 to 70 months) (p=0.001), but remained similar in HIV-infected children (70 
months; IQR, 38 to 93 months; p=0.933). The median age in HIV-uninfected children 
increased from 11 months (IQR, 7 to 38 months) to 36 months (IQR, 14 to 109 months) 
(p<0.001) between 2005 to 2011, and then decreased to 15 months (IQR, 5 to 34 
months) (p=0.008) in 2012.  
 
Most (n=369; 65.2%) children were underweight for age with a median weight-for-age Z-
score of -2.73 (Range, -8.89 to 5.51) for children <10 years of age. 
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The in-hospital case fatality rate over the eight year period was 2.6% (95% CI, 1.7-
3.9%). Of the 25 children with culture-confirmed PTB who died during the eight year 
study period, 14 (56%) were HIV-infected and the HIV-status was not ascertained in six 
(24%) cases. Sixteen (64%) of the 25 deaths occurred in children under two years of 
age. None of these 16 children had significant blood culture isolates on admission to 
hospital. 
  
3.3 Trends in the incidence of culture-confirmed PTB 
There was a steady decline in annual number of culture-confirmed PTB hospitalizations, 
from 216 in 2005 to 62 by 2012 (Table 1). The decline was most evident in the 3-11 
month and 60-179 month age-groups. This included a decrease from 88 cases in 2005 
to 17 cases in 2012 in the 3-11 month age-group, and from 64 cases in 2005 to 19 
cases in 2012 in the 60-179 month age-group. The number of cases decreased in all 
age categories among HIV-infected children, whilst the decrease was primarily evident 
in the 3-11 month age group in HIV-uninfected children (Table 2).  
 
The overall incidence of culture-confirmed PTB (per 100 000) decreased by 69.2% 
(95% CI, 62.8-74.6%) when comparing Period 1 (47.9; 95% CI, 44.6-51.7) to Period 3 
(14.8; 95% CI, 12.3-17.6) (Table 3). The percentage reduction in culture-confirmed PTB 
between Periods 1 and 3 was most evident in HIV-infected (80.5%; 95% CI, 73.8-
85.5%) than in HIV-uninfected children (34.8%; 95% CI, 14.9-50.1%) when looking at all 
age categories combined (Table 3). 
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Table 1: Demographic data of children hospitalized with culture-confirmed PTB 
Year 2005 2006 2007 2008 2009 2010 2011 2012 Total 
PCV eras Period 1  
(Pre-PCV era) 
Period 2  
(Transitional PCV era) 
Period 3  
(PCV era) 
Total no. of cases   216 211 136 104 84 73 64 62 950 
Age 
(months) 
3-11   88 (41%) 82 (39%) 46 (34%) 31 (30%) 23 (27%) 15 (21%) 8 (13%) 17 (27%) 310 (33%) 
12-23  35 (16%) 38 (18%) 24 (18%) 16 (15%) 11 (13%) 7 (10%) 12 (19%) 14 (23%) 157 (17%) 
24-59  29 (13%) 38 (18%) 23 (17%) 26 (25%) 15 (18%) 16 (22%) 17 (27%) 12 (19%) 176 (19%) 
60-179 64 (30%) 53 (25%) 43 (32%) 31 (30%) 35 (42%) 35 (48%) 27 (42%) 19 (31%) 307 (32%) 
Median age 
(range): All  
HIV-infected 
HIV-uninfected 
 
19 (3-176) 
21(3-158) 
11 (3-170) 
 
17 (3-173) 
22 (3-173) 
15 (3-160) 
 
23 (3-170) 
55 (3-170) 
16 (3-159) 
 
27 (3-167) 
55 (3-167) 
21 (3-156) 
 
34 (3-163) 
88 (3-163) 
22 (3-160) 
 
59 (3-178) 
92 (3-174) 
22 (3-178) 
 
48 (5-167) 
78 (3-167) 
36 (3-159) 
 
24 (3-165) 
70 (3-165) 
15 (3-159) 
 
25 (3-178) 
47 (3-174) 
17 (3-178) 
Gender Male 112 (52%) 114 (54%) 76 (56%) 52 (50%) 50 (60%) 29 (40%) 39 (61%) 33 (53%) 505 (53%) 
Weight for 
Age (WAZ) 
(in children 
<10 years) 
Median Z-score 
 
-2.81 -2.74 -3.18 -2.89 -2.94 -2.51 -2.05 -2.59 -2.73 
Range -7.14 – 1.87 -7.83 – 4.39 -8.89 – 1.8 -7.31 – 1.44  -6.29 – 5.51 -5.4 – 1.8 -5.21 – 1.31 -7.61 – 0.08 -8.89 – 5.51 
% WAZ <-2 54% 38% 36% 41% 58% 55% 46% 43% 45% 
HIV status:            
3-179 
months 
HIV-infected 127 (59%) 112 (53%) 80 (59%) 55 (53%) 48 (57%) 42 (58%) 29 (45%) 21 (34%) 514 (54%) 
HIV- uninfected 56 (26%)                 68 (32%) 41 (30%) 42 (40%) 35 (42%) 30 (41%) 34 (53%) 39 (63%) 345 (36%) 
HIV unknown 33 (15%) 31 (15%) 15 (11%) 7 (7%) 1 (1%) 1 (1%) 1 (2%) 2 (3%) 91 (10%) 
Outcomes Discharged 169 (78%) 193 (92%) 125 (92%) 96 (92%) 81 (96%) 70 (96%) 62 (97%) 61 (98%) 857 (90%) 
Demised 5 (2%) 5 (2%) 3 (2%) 5 (5%) 2 (2%) 2 (3%) 2 (3%) 1 (2%) 25 (3%) 
Unknown 42 (19%) 13 (6%) 8 (6%) 3 (3%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 68 (7%) 
Case fatality 
proportion 
(95% CI)  
2.3  
(0.8 – 5.4) 
2.4  
(0.8 – 5.5) 
2.2  
(0.5 – 6.4) 
4.8  
(0.2 – 11.2) 
2.4  
(0.3 -8.6) 
2.7  
(0.3 – 9.9) 
3.1 
(0.4 – 11.3) 
1.6  
(0.04 – 9.0) 
2.6 
(1.7 – 3.9) 
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Table 2: Number of cases hospitalized for culture-confirmed PTB stratified by age and HIV status 
Year 2005 2006 2007 2008 2009 2010 2011 2012 Total 
PCV eras Period 1  
(Pre-PCV era) 
Period 2  
(Transitional PCV era) 
Period 3  
(PCV era) 
Combined 
3-11 
months 
HIV-infected 50 (57%) 42 (51%) 22 (48%) 14 (45%) 9 (39%) 5 (33%) 4 (50%) 2 (12%) 148 (48%) 
HIV-uninfected 29 (33%) 26 (32%) 17 (37%) 14 (45%) 13 (57%) 10 (67%) 4 (50%) 13 (77%) 126 (41%) 
HIV unknown 9 (10%) 14 (17%) 7 (15%) 3 (10%) 1 (4%) 0 (0%) 0 (0%) 2 (12%) 36 (12%) 
Total: 3-11 months 88 82 46 31 23 15 8 17 310 
12-23 
months 
HIV-infected 17 (49%) 16 (42%) 8 (33%) 5 (31%) 5 (46%) 1 (14%) 3 (25%) 1 (7%) 56 (36%) 
HIV-uninfected 10 (29%) 18 (47%) 14 (58%) 11 (69%) 6 (55%) 5 (71%) 9 (75%) 13 (93%) 86 (55%) 
HIV unknown 8 (23%) 4 (11%) 2 (8%) 0 (0%) 0 (0%) 1 (14%) 0 (0%) 0 (0%) 15 (10%) 
Total: 12-23 months 35 38 24 16 11 7 12 14 157 
24-59 
months 
HIV-infected 17 (59%) 17 (45%) 15 (65%) 11 (42%) 6 (40%) 10 (63%) 6 (35%) 6 (50%) 88 (50%) 
HIV-uninfected 7 (24%) 14 (37%) 5 (22%) 11 (42%) 9 (60%) 6 (38%) 11 (65%) 6 (50%) 69 (39%) 
HIV unknown 5 (17%) 7 (18%) 3 (13%) 4 (15%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 19 (11%) 
Total: 24-59 months 29 38 23 26 15 16 17 12 176 
60-179 
months 
HIV-infected 43 (67%) 37 (70%) 35 (81%) 25 (81%) 28 (80%) 26 (74%) 16 (59%) 12 (63%) 222 (72%) 
HIV-uninfected 10 (16%) 10 (19%) 5 (12%) 6 (19%) 7 (20%) 9 (26%) 10 (37%) 7 (37%) 64 (21%) 
HIV unknown 11 (17%) 6 (11%) 3 (7%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 21 (7%) 
Total: 60-179 months 64 53 43 31 35 35 27 19 307 
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 Table 3: Incidence of culture-confirmed PTB for Period 1 to Period 3 in 
children 3-179 months of age 
  
Incidence of PTB
1 
(95% CI) [N of PTB cases] IRR comparing 
the Pre-PCV 
and 
Transitional 
PCV eras
2
 
(95% CI) 
 
IRR 
comparing 
the 
Transitional 
PCV and 
PCV eras
3
 
(95% CI) 
IRR 
comparing 
the Pre-
PCV and 
PCV eras
4
 
(95% CI) 
 
% reduction 
and P-value 
comparing Pre-
PCV and PCV 
eras 
(95% CI) 
 
 Period 1  
(Pre-PCV era) 
(2005-2008) 
Period 2  
(Transitional-PCV 
era) 
 (2009-2010) 
Period 3  
(PCV era) 
(2011-2012) 
    
Overall 47.9 (44.4-51.7) 
[667] 
21.3 (18.1-25.0) 
[157] 
14.8 (12.3-17.6) 
[126] 
0.45 (0.37-
0.53) 
0.69 (0.55-
0.87) 
0.31 (0.25-
0.37) 
69.2 (62.8-
74.6); p<0.001 
HIV-
infected 
 
1,144.9  
(1,032.4-1,266.2) 
[374] 
441.2  
(355.0-542.1) 
[90] 
223.2  
(165.7-294.2) 
[50] 
0.39 (0.31-
0.49) 
0.51 (0.36-
0.71) 
0.20 (0.15-
0.26) 
80.5 (73.8-
85.5); p<0.001 
HIV-
uninfected 
15.2 (13.2-17.5) 
[207] 
9.1 (7.0-11.6) 
[65] 
9.9 (7.8-12.5) 
[73] 
0.60 (0.45-
0.79) 
1.09 (0.78-
1.52) 
0.65 (0.50-
0.85) 
34.8 (14.9-
50.1); p=0.002 
HIV-
infected 
EX
5
 
1,313.3  
(1,192.6-1,442.7) 
[429] 
446.1 (359.4-547.5) 
[91] 
218.8 (161.9-
289.1) 
[49] 
0.34 (0.27-
0.43) 
0.49 (0.35-
0.69) 
0.17 (0.12-
0.22) 
83.3 (77.6-
87.6); p<0.001 
HIV-
uninfected 
EX
6
 
17.5 (15.4-19.9) 
[238] 
9.2 (7.1-11.7) 
[66] 
10.2 (8.0-12.8) 
[75] 
0.53 (0.40-
0.69) 
1.10 (0.79-
1.54) 
0.58 (0.45-
0.76) 
41.8 (24.5-
55.1); p<0.001 
HIV-
uninfected 
EX
7
 
21.6 (19.2-24.2) 
[293] 
9.4 (7.3-11.9) 
[67] 
10.3 (8.1-12.9) 
[76] 
0.43 (0.33-
0.57) 
1.10 (0.79-
1.53) 
0.48 (0.37-
0.62) 
52.1 (38.3-
62.8); p<0.001 
¹ Number of cases per 100 000 
² IRR = Incidence risk ratios IRR: Period 1 vs. Period 2  
3
 IRR = Incidence risk ratios IRR: Period 2 vs. Period 3 
4 
IRR = Incidence risk ratios IRR: Period 1 vs. Period 3 
 5 
Incidence of PTB in HIV-infected extrapolated proportionally to include HIV-unknown as HIV-infected and HIV-uninfected 
 6
 Incidence of PTB in HIV-uninfected extrapolated proportionally to include HIV-unknown as HIV-infected and HIV-uninfected 
 7 
Incidence of PTB in HIV-uninfected extrapolated to include all cases with HIV-unknown as HIV-uninfected 
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Despite the decline in incidence (per 100 000) of culture-confirmed PTB in HIV-infected 
children, the incidence remained 22-fold higher in Period 3 (223.2; 95% CI, 165.7-
294.2) compared to that observed in HIV-uninfected children (9.9; 95% CI, 7.8-12.5). 
 
3.4 Trends in the incidence of culture-confirmed PTB stratified by age 
The decline in culture-confirmed PTB incidence when comparing Period 1 and Period 3 
was most marked in the two youngest age categories; i.e. 81.3% (95% CI, 71.8-87.6; 
p<0.001) in 3-11 months of age and 55.5% (95% CI, 31.8-70.9%; p<0.001) in 12-23 
months of age (Figure 2). 
 
The incidence of culture-confirmed PTB in HIV-infected children decreased in all age 
categories when comparing Periods 1 and 3 (p<0.001) (Figure 3), whereas the decline 
in HIV-uninfected children was only significant in the 3-11 month age-category; IRR 
0.36 (95% CI, 0.21-0.61; p<0.001) (Figure 4). 
 
The incidence of culture-confirmed PTB among HIV-uninfected children in the 12-23 
month age category comparing Periods 2 and 3 was similar. 
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Figure 2: Incidence trends in culture-conformed PTB by PCV-Period: All children 
3-11 months:     IRR Period 1 vs 2: 0.31 (95% CI, 0.22-0.43; p<0.001); 55.5% (95%CI; 47.0-62.6%)* 
                              IRR Period 2 vs 3: 0.61 (95% CI, 0.37-1.01; p=0.051); 39.1% (95%CI, -0.10-63.2%)* 
                              IRR Period 1 vs 3: 0.19 (95% CI, 0.12-0.28; p<0.001); 81.3% (95% CI, 71.8-87.6%)* 
12-23 months:   IRR Period 1 vs 2: 0.32 (95% CI, 0.20-0.53; p<0.001); 67.9% (95% CI, 47.2-80.5%)* 
                              IRR Period 2 vs 3: 1.39 (95% CI, 0.76-2.53; p=0.286); 27.8% (95% CI, -31.7-60.4%)* 
                              IRR Period 1 vs 3: 0.45 (95% CI, 0.29-0.68; p<0.001); 55.5% (95% CI, 31.8-70.9%)* 
24-59 months:   IRR Period 1 vs 2: 0.54 (95% CI, 0.36-0.80; p=0.002); 46.2% (95% CI, 20.1-63.8%)* 
                              IRR Period 2 vs 3: 0.93 (95% CI, 0.56-1.55; p=0.783); 6.9% (95% CI, -54.5-43.9%)* 
                              IRR Period 1 vs 3: 0.48 (95% CI, 0.32-0.73; p<0.001); 51.7% (95% CI, 27.0-68.0%)* 
60-179 months: IRR Period 1 vs 2: 0.67 (95% CI, 0.51-0.88; p=0.004); 32.8% (95% CI, 11.6-48.9%)* 
                               IRR Period 2 vs 3: 0.64 (95% CI, 0.44-0.92; p=0.017); 36.3% (95% CI, 7.6-56.1%)* 
                               IRR Period 1 vs 3: 0.50 (95% CI, 0.33-0.75; p<0.001); 49.9% (95% CI, 24.8-66.7%)* 
*Percentage reduction 
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Figure 3: Incidence trends in culture-conformed PTB by PCV-Period: HIV-infected 
children 
3-11 months:     IRR Period 1 vs 2: 0.30 (95% CI, 0.17-0.51; p<0.001); 70.4% (95% CI; 48.7-82.9%)* 
                             IRR Period 2 vs 3: 0.41 (95% CI, 0.16-1.07; p=0.058); 60.0% (95% CI, 64.6-84.2%)* 
                             IRR Period 1 Vs 3: 0.12 (95% CI, 0.05-0.28; p<0.001); 88.0% (95% CI, 73.0-94.6%)* 
12-23 months:   IRR Period 1 vs 2: 0.26 (95% CI, 0.11-0.60; p<0.001); 74.3% (95% CI, 40.0-89.0%)* 
                              IRR Period 2 vs 3: 0.72 (95% CI, 0.21-2.56; p=0.615); 27.6% (95% CI, -156.1-79.5%)* 
                              IRR Period 1 vs 3: 0.19 (95% CI, 0.07-0.52; p<0.001); 81.4% (95% CI, 48.5-93.3%)* 
24-59 months:   IRR Period 1 vs 2: 0.52 (95% CI, 0.30-0.91; p=0.019); 47.6% (95% CI, 9.2-69.8%)* 
                              IRR Period 2 vs 3: 0.85 (95% CI, 0.40-1.79; p=0.660); 15.4% (95% CI, -78.6-60.0%)* 
                              IRR Period 1 vs 3: 0.44 (95% CI, 0.24-0.82; p=0.008); 55.7% (95% CI, 17.8-76.2%)* 
60-179 months: IRR Period 1 vs 2: 0.45 (95% CI, 0.33-0.61; p<0.001); 55.1% (95% CI, 38.6-67.2%)* 
                              IRR Period 2 vs 3: 0.42 (95% CI, 0.26-0.65; p<0.001); 58.6% (95% CI, 34.6-73.7%)* 
                              IRR Period 1 vs 3: 0.19 (95% CI, 0.12-0.28; p<0.001); 81.4% (95% CI, 72.1-87.6%)* 
*Percentage reduction 
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Figure 4: Incidence trends in culture-conformed PTB by PCV-Period: All children: 
HIV-uninfected children
3-11 months:     IRR Period 1 vs 2: 0.53 (95% CI, 0.33-0.83; p=0.005); 47.4% (95% CI; 16.7-66.8%)* 
                             IRR Period 2 vs 3: 0.68 (95% CI, 0.37-1.28; p=0.230); 31.7% (95% CI, -28.8-63.5%)* 
                            IRR Period 1 Vs 3: 0.36 (95% CI, 0.21-0.61; p<0.001); 64.1% (95% CI, 39.6-78.6%)* 
12-23 months:   IRR Period 1 vs 2: 0.42 (95% CI, 0.22-0.80; p=0.007); 58.1% (95% CI, 19.8-78.1%)* 
                             IRR Period 2 vs 3: 1.91 (95% CI, 0.93-3.93; p=0.075); 47.6% (95% CI, (-8.1-74.6%)* 
                            IRR Period 1 vs 3: 0.80 (95% CI, 0.49-1.32; p=0.377); 20.0% (95% CI, -31.5-51.4%)* 
24-59 months:   IRR Period 1 vs 2: 0.93 (95% CI, 0.52-1.64; p=0.790); 7.5% (95% CI, -64.4-47.6%)* 
                             IRR Period 2 vs 3: 0.99 (95% CI, 0.51-1.94; p=0.978); 0.9% (95% CI, -94.0-49.4%)* 
                            IRR Period 1 vs 3: 0.92 (95% CI, 0.52-1.63; p=0.770); 8.3% (95% CI, -62.8-48.4%)* 
60-179 months: IRR Period 1 vs 2: 0.96 (95% CI, 0.52-1.75; p=0.880); 4.5% (95% CI, -74.6-47.8%)* 
                              IRR Period 2 vs 3: 1.04 (95% CI, 0.52-2.05; p=0.921); 3.4% (95% CI, -91.2-51.2%)* 
                             IRR Period 1 vs 3: 0.99 (95% CI, 0.55-1.79; p=0.978); 1.2% (95% CI, -78.6-45.3%)* 
*Percentage reduction 
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3.5. The 3-term moving average and regression analysis of incidence of culture-
confirmed TB in HIV-infected and -uninfected children stratified by age (Figure 5) 
The 3- term moving average showed a decreasing trend, particularly  in the 2 youngest 
age-categories, in the incidence of culture-confirmed PTB in hospitalized children in 
HIV-infected and –uninfected children.  
 
Although the regression analysis showed a significant decline in the incidence of 
culture-confirmed TB from 2005 to 2009 in age-groups 3 months to <2 years and 2 
years to <5 years as previously reported (8), the low incidence of culture-confirmed PTB 
at the time of PCV introduction precluded any further analysis being undertaken with 
regard to the association of PCV introduction on the year-on-year decline in 
hospitalization for culture-confirmed PTB in HIV-infected (Figure 5) and HIV-uninfected 
children of all age-groups. 
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(A) 
 
 
(B) 
 
Figure 5: Three-term moving average showing the incidence of culture-confirmed 
TB in HIV-infected (A) and -uninfected (B) children stratified by age 
 
Legend:  Age 1: 3-11 months 
          Age 2: 12-23 months 
          Age 3: 24-59 months 
          Age 4: 60-179 months 
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3.6 Immunological classification in HIV-infected children hospitalized with PTB (Table 4) 
Three hundred and eighty nine (76.0%) of the 514 HIV-infected cases had CD4+ 
lymphocyte counts done within three months of PTB diagnosis. Two hundred and sixty 
eight (68.9%) of these patients were categorized as severely immunocompromised. The 
number of HIV-infected children with available CD4+ counts increased significantly 
during the study time-period (test-for-trend, p=0.039), however, the proportion of 
severely immunocompromised children was similar across the eight year period. The 
mean CD4 percentage was 14% (Standard Deviation [SD], 10%). 
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Table 4: WHO immunological classification* for established HIV infection in children hospitalized for culture-
confirmed PTB  
Year PTB 
cases 
HIV-infected 
(% of PTB 
cases) 
HIV-infected with 
available CD4 results 
(% of HIV-infected 
PTB cases) 
Degree of Immunosuppression*                                   
 Not significant Mild Advanced Severe 
2005 216 127 (58.8%) 90 (70.9%) 9 (10.0%) 6 (6.7%) 10 (11.1%) 65 (72.2%) 
2006 211 112 (53.1%) 77 (68.8%) 9 (11.7%) 3 (3.9%) 10 (13.0%) 55 (71.4%) 
2007 136 80 (58.8%) 55 (68.8%) 3 (5.5%) 3 (5.5%) 9 (16.4%) 40 (72.7%) 
2008 104 55 (52.9%) 43 (78.2%) 3 (7.0%) 2 (4.7%) 10 (23.3%) 28 (65.1%) 
2009 84 48 (57.1%) 46 (95.8%) 4 (8.7%) 3 (6.5%) 4 (8.7%) 35 (76.1%) 
2010 73 42 (57.5%) 33 (78.6%) 3 (9.1%) 3 (9.1%) 9 (27.3%) 18 (54.5%) 
2011 64 29 (45.3%) 25 (96.2%) 6 (24.0%) 2 (8.0%) 3 (12.0%) 14 (56.0%) 
2012 62 21 (33.9%) 20 (95.2%) 4 (20.0%) 0 (0.0%) 3 (15.0%) 13 (65.0%) 
Total 950 514 (54.1%) 389 (75.7%) 41 (10.5%) 22 (5.7%) 58 (14.9%) 268 (68.9%) 
 WHO immunological classification for established HIV infection (CD4% or absolute number per mm3) (43) (Appendix 3, page 41)  
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3.7 Culture-confirmed PTB with concurrent bacterial infections (Table 5)     
Eight hundred and sixty two (90.7%) of the 950 children with culture-confirmed PTB had 
blood cultures done at the time of their admission to hospital (Table 5). Concurrent 
bacteraemia was identified among 37 (6.2%) of 594 cases, five (3.4%) of 146 cases and 
three (2.5%) of 122 PTB cases in Periods 1, 2 and 3, respectively. The proportion of 
non-contaminated blood cultures with significant isolates decreased during the study 
time-period (test-for-trend, p=0.012). In period 1, 28 (80%) of the 37 cases were HIV-
infected compared to 4 (80%) out of 5 cases in period 2 and 3 (100%) of 3 cases in 
period 3. 
 
Of the 45 patients with significant bacteremia, 34 (75.6%) were HIV-infected and the 
isolates (Table 6) were S. pneumoniae (n=8), Methicillin-sensitive Staphylococcus 
aureus (n=6), Methicillin-resistant S. aureus (n=1), Enterococcus faecalis (n=2), 
Streptococcus bovis (n=1), Escherichia coli (n=5), Salmonella spp (n=5), Haemophilus 
influenzae (n=3), extended-spectrum ß-lactamase (ESBL) producing Klebsiella 
pneumoniae (n=1), Shigella flexneri (n=1) and dual Klebsiella pneumoniae and Proteus 
mirabilis infection (n=1).  Eight (17.7%) patients with significant bacteremia were HIV-
uninfected and 3 (6.7%) were HIV-unknown. 
 
The odds of having a blood culture positive for pneumococcus was 1.91-fold (95% CI, 
0.26-84.56) greater in the Pre-PCV era, p=1.000 (exact). The numbers were too small 
to show statistical significance, although the trend was for reduced pneumococcal 
bacteraemia in the PCV era.
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Table 5: Admission blood culture results of cases hospitalized with culture-confirmed PTB 
Year 2005 2006 2007 2008 2009 2010 2011 2012 Total 
PCV eras Period 1  
(Pre-PCV era) 
Period 2  
(Transitional PCV era) 
Period 3  
(PCV era) 
Combined 
TOTAL 216 211 136 104 84 73 64 62 950 
Negative 154 
(71.3%) 
135 
(64.0%) 
92 (67.6%) 76 (73.1) 56 (66.7%) 52 (71.2%) 52 (81.3%) 49 (79.0%) 666 
(70.1%) 
Blood culture not done 18 (8.3%) 28 (13.3%) 15 (11%) 12 (11.5%) 5 (6.0%) 6 (8.2%) 1 (1.6%) 3 (4.8%) 88 (9.3%) 
Significant blood culture isolates 14 (6.5%) 14 (6.6%) 6 (4.4%) 3 (2.9%) 3 (3.6%) 2 (2.7%) 2 (3.1%) 1 (1.6%) 45 (4.7%) 
 
 
 
Gram-positive 
organisms 
Streptococcus pneumoniae  4  3  2  0  1  0  1  0  11 
Staphylococcus aureus  2  1  1  0  1  0  0  1  6 
Methicillin-resistant 
Staphylococcus aureus 
 1  0  0  0  0  0  0  0  1 
Enterococcus faecalis  0  0  1  1  1  0  0  0  3 
Streptococcus bovis  0  0  0  1  0  0  0  0  1 
Staphylococcus aureus + 
Enterococcus faecalis 
 1  0  0  0  0  0  0  0  1 
Gram-negative 
organisms 
Escherichia coli  2  5  1  0  0  0  0  0  8 
Salmonella spp  3  2  1  0  0  0  0  0  6 
Haemophilus influenzae  1  1  0  1  0  0  0  0  3 
Klebsiella pneumoniae 
ESBL* 
 0  0  0  0  0  0  1  0  1 
Moraxella catarrhalis  0  0  0  0  0  1  0  0  1 
Shigella flexneri  0  0  0  0  0  1  0  0  1 
Neisseria meningitidis  0  1  0  0  0  0  0  0  1 
Klebsiella pneumoniae + 
Proteus mirabilis 
 0  1  0  0  0  0  0  0  1 
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Presumed Contaminants 30 
(13.9%) 
34 (16.1%) 23 (16.9%) 13 (12.5%) 20 (23.8%) 13 (17.8%) 9 (14.1%) 9 (14.5%) 151 
(15.9%) 
 Coagulase negative 
staphylococcus 
 19  23  14  5  14  7  6  3  91 
Bacillus spp  3  4  1  2  1  2  1  1  15 
Corynebacterium spp  1  2  3  2  3  1  2  0  14 
Micrococcus spp  3  3  1  2  0  0  0  1  10 
Viridans streptococci   2  1  2  2  0  1  0  1  9 
Streptococcus salivarius  0  0  0  0  0  1  0  0  1 
Lactobacillus spp  0  0  0  0  0  0  0  1  1 
Viridans streptococci + 
Coagulase negative 
staphylococcus 
 1  0  1  0  0  0  0  1  3 
Coagulase negative 
staphylococcus + 
Corynebacterium spp 
 0  1  0  0  1  0  0  0  2 
Enterococcus faecium +       
Coagulase negative 
staphylococcus 
 0  0  0  0  0  1  0  0  1 
Acinetobacter baumannii + 
Coagulase negative 
staphylococcus 
 0  0  0  0  0  0  0  1  1 
Staphylococcus aureus + 
Bacillus spp 
 0  0  0  0  1  0  0  0  1 
Methicillin-resistant 
Staphylococcus areus + 
Viridans streptococci 
 0  0  1  0  0  0  0  0  1 
Viridans streptococci + 
Bacillus spp 
 1  0  0  0  0  0  0  0  1 
* ESBL = extended-spectrum ß-lactamase  
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4.0 DISCUSSION 
This study demonstrates a significant reduction in the incidence of hospitalization for 
culture-confirmed PTB in Sowetan children. This included a 69.2% (95% CI, 62.8-74.6) 
reduction in hospitalization for culture-confirmed PTB in children 3-179 months of age in 
Period-1 compared to Period-3 (Table 3). When analysing the data stratified by HIV 
status, the decline was greatest in HIV-infected children across all age groups, 
particularly the 3-11 month age category (Figure 3). Although there was a decline in the 
incidence of hospitalization with culture-confirmed PTB in all age categories in HIV-
uninfected children, this was only statistically significant in the 3-11 month age category 
(Figure 4). The improved access to ART in HIV-infected children could be the major 
factor that contributed to the reduction of culture-confirmed PTB these children (8). 
Although we had hypothesized that the implementation of PCV could have affected the 
incidence of PTB hospitalization, the incidence of culture confirmed PTB prior to the 
introduction of PCV had been reduced to low rates, which limited any robust measure 
as to whether there was a temporal association between PCV immunization and 
incidence of culture-confirmed PTB hospitalization in our study setting. We did, 
however, observe a trend toward lower prevalence of concurrent bacteremia over the 
study period, the most common pathogen of which was S. pneumoniae in the pre-PCV 
era and which was uncommon in the PCV era.   
 
The only comparative study that has looked at the incidence of hospitalization of 
culture-confirmed PTB associated with PCV (9-valent formulation) vaccination was a 
vaccine probe study conducted in Soweto from 1997-2003 (25). This vaccine probe 
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study indicated that hospitalization for culture-confirmed PTB was 43% (95% CI, 9.7-
65.1%) less likely among children vaccinated with PCV compared to placebo recipients. 
Furthermore, the decline in culture-confirmed PTB hospitalization was significant only in 
HIV-infected children (25). Reductions in hospitalization for culture-confirmed PTB in the 
context of access to PCV suggest that pneumococcal pneumonia is a precipitating 
illness which prompts admission to hospital in children with PTB residing in high-
burdened TB settings. Immunologic perturbations associated with TB may predispose 
affected children to developing bacterial community acquired pneumonia (25, 30, 31).  
 
In comparison to the vaccine-probe study, our study also showed a significant reduction 
in culture-confirmed PTB in HIV-uninfected children in the 3-11 month age group. The 
3-11 month age category was the category with the highest burden of hospitalization for 
culture-confirmed PTB in Period 1 but also had the largest reduction in the incidence of 
hospitalization for culture-confirmed PTB when comparing Period 1 and Period 3 
(Figures 2, 3 and 4). Children in the 3-11 month age category were programmatically 
targeted to have received three doses of PCV (at ages 6 and 14 weeks, and 9 months 
of age) according to the EPI, and introduction of this vaccine was a major public health 
intervention between Period 1 and Period 3. The youngest child vaccinated with the 
third dose of PCV in South Africa would have been 3 years and 8 months old on the 
31st December 2012 (the cut-off date for inclusion in the analysis of the present study), 
as PCV was introduced in the EPI in April 2009. The national coverage of the third dose 
of PCV in South Africa was reported by WHO to be 10% in 2009, increasing to 89% in 
2011 (38). This suggests that by 2011 and 2012, only in the 3-11 month age category 
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would the majority of children have been fully vaccinated. Of note, there was no catch-
up campaign of PCV immunisation at the time of introduction of PCV7 into the South 
African EPI in 2009. Therefore, the true impact of PCV on hospitalizations for culture-
confirmed PTB would not be seen in the older age categories using the time scale cut-
offs of the present analysis.   
 
It is well documented that ART reduces the incidence of TB in HIV-infected children (7-
10).  In 2010 the South African Department of Health implemented further 
improvements in HIV prevention and care programs in the country. These included 
changes to the PMTCT program as well as starting all HIV-infected infants on ART 
regardless of immunologic staging of disease across the country, including our study 
population (45). A study conducted at CHBAH showed that the up-scaling of the ART 
program in South Africa has been associated with a significant decline in the incidence 
of culture-confirmed TB between 2005 and 2009, more so in HIV-infected (70.6%; p < 
0.0001) than HIV-uninfected (41.3%; p = 0.0003) children in the era before PCV was 
introduced into the South African EPI (8), which suggests that access to ART was the 
main driver of reductions in culture-confirmed PTB hospitalizations. By 2010, a high 
proportion (94.8%) of children with AIDS in Gauteng were already on ART (32). This 
would mean that children would have been more immune reconstituted.  
 
Another potential contributing factor for declining culture-confirmed PTB in children 
would be a reduction in transmission of MTB from adult PTB cases to children in 
households and the community at large; however, this scenario is unlikely to be 
34 
 
occurring in our setting as the South African TB incidence has continued to escalate 
over the past number of years (from 940 per 100 000 population in 2006 to 1003 per 
100 000 population in 2012) (46, 47).  
.   
The median age at hospitalization in ‘all’ (HIV-infected and HIV-uninfected) children with 
culture-confirmed PTB increased over time from 2005 to 2010/11, and then decreased. 
This is an expected finding, as the decline in culture-confirmed PTB was greatest in 
infants, most probably due to ART initially from 2005, accelerated by PCV from 2009 
onwards. The subsequent decrease in median age at hospitalisation with culture-
confirmed PTB in 2011 and 2012 may be due to improved management of older HIV-
infected children with ART. 
 
Significant blood culture yields were observed in 4.7% of children hospitalized with 
culture-confirmed PTB (Table 5). This was lower than in a previous South African study 
on severe pneumonia, which reported bacteremia in 7% of HIV-uninfected children with 
severe pneumonia and 15% of HIV-infected children in the pre-ART, pre-PCV era (4). 
This could be due to pneumococcal infections that were not being prevented in that 
study prior to PCV immunization, as the pneumococcus constituted the majority (10.1%) 
of blood culture isolates (4). Although the trend was for reduced pneumococcal 
bacteraemia in the PCV era, the numbers were too small to show statistical 
significance. There was also a decline in all significant blood culture isolates from 2005 
(6.5%) to 2012 (1.6%) (Table 5). Therefore, other factors could have also influenced this 
decline. Studies in developed countries have reported bacteremia in 2-4% of childhood 
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acute pneumonia episodes (51, 52). Although blood culture yield is low, a significant 
blood culture result is indicative of the bacterial pathogen contributing to infection and 
could guide appropriate antibiotic therapy. The high blood culture contamination rates 
observed in our study (15.9% overall) may have impaired the identification of significant 
pathogens. 
 
HIV-infected children with low CD4 counts are at increased risk of hospitalization with 
culture-confirmed PTB. The mean CD4 percentage in this study was 14% (SD, 10%) 
and 69% of all HIV-infected children hospitalized for culture-confirmed PTB in our study 
were severely immunocompromised (Table 4). Other studies have also reported low 
CD4 counts in HIV-infected children with culture-confirmed TB, with mean CD4 
percentages of 21% (SD, 11%) (48).  
 
The case fatality rate in our study (2.6%; 95% CI, 1.7-3.9%) was similar to case fatality 
rates (2.3%; 95% CI, 1·6–3·4) for severe acute lower respiratory tract infections in 
children under-5 years of age treated in developing countries, and in children with TB in 
another African study (3.9%) (49, 50). 
 
4.1 Study Limitations 
An important limitation in this study is that the incidence of culture confirmed PTB prior 
to the introduction of PCV had been reduced to low rates, which hampered any robust 
measure as to whether there was a reduction of culture-confirmed PTB prior to the 
introduction of PCV into the South African EPI due to improved access to ART. 
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Another limitation in this study is the possible disadvantages of the retrospective 
ecological study design that makes it difficult to detect complicated exposure-outcome 
relationships and may show association at the population level which may not exist at 
the individual level.   
 
A further limitation of this study is that we have not taken into account whether access 
to INH preventive treatment (IPT) as prophylaxis against TB in children at risk who have 
a close contact with PTB, has increased over the study time frame. If access to and 
utilization of IPT has increased in the recent past in the study setting, this would be 
expected to have decreased the burden of paediatric culture-confirmed PTB in the study 
setting. A Cape Town study showed that IPT may offer additional protection against TB 
in immuncompromised HIV-infected children on ART (53), however, another study failed 
to show any benefit of primary IPT in improving TB disease-free survival among HIV-
infected children or TB infection-free survival among HIV-uninfected children immunized 
with BCG vaccine (54). The uptake of IPT as part of the integrated preventative 
approach amongst TB-exposed household contacts, including children of newly 
diagnosed infectious PTB cases, is suboptimal at best in high-burdened settings in 
South Africa (55). 
 
Another parameter which may cloud the intended outcomes of the study would have 
been altered clinician-initiated investigation of children with suspected PTB at the 
hospital. We cannot with confidence exclude a reduced detection of culture-confirmed 
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PTB cases in the latter stage of the study due to changes in clinical practice which may 
have resulted in fewer children with suspected PTB being sampled by submission of 
gastric washings. This is because we did not match number of gastric washings 
submitted per individual case of suspected PTB to the numbers of gastric washings 
submitted per year. However, there were 61 to 86 gastric washings submitted per 100 
paediatric admissions between 2005 and 2012; p=0.614 (test-for-trend) and 1.6 to 2.7 
gastric washings submitted per LRTI admitted between 2005 and 2012; p=0.488 (test-
for-trend). As there were no significant trends towards a reduction in the number of 
gastric washings submitted per 100 paediatric admissions to the hospital, or the 
numbers of gastric washings submitted per paediatric LRTI case in the study time 
period, it is reasonable to assume that significant changes in clinical practice did not 
occur at the institution between 2005 and 2012.
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5.0 CONCLUSION 
There has been a significant decline in culture-confirmed PTB hospitalization in children 
comparing the pre-PCV to the PCV-era. However, the incidence of culture-confirmed 
PTB prior to the introduction of PCV had been reduced to low levels due to antiretroviral 
therapy. This confounder together with the retrospective ecological study design and 
other several possible confounders limited any robust estimate as to whether there was 
a temporal association between PCV immunization and incidence of culture-confirmed 
PTB hospitalization in our study setting. We did, however, observe a trend toward lower 
prevalence of concurrent bacteremia over the study period, the most common pathogen 
of which was S. pneumoniae in the pre-PCV era and which was uncommon in the PCV 
era. 
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6.0 RECOMMENDATIONS 
This study might not have shown the full impact of PCV on culture-confirmed PTB, as 
we focused on the initial years after PCV was introduced in this analysis. It will be useful 
to reappraise the impact of PCV on hospitalization for culture-confirmed PTB over a 
more extended period which incorporates an experience since the roll out of PCV13. 
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7.0 Appendix 
Appendix 1: Percentage of children with Acquired Immunodeficiency Syndrome 
that were on Antiretroviral Therapy in Gauteng (32) 
 2005 2006 2007 2008 2009 2010 2011 2012 
Total number of 
children with AIDS 
6709 8911 11884 14176 17867 21599 24519 26812 
Number of children 
with AIDS, on ART 
2721 5782 8133 11142 16859 20469 23435 25772 
Number of children 
with AIDS, not on 
ART 
3988 3129 3751 3034 1008 1130 1084 1040 
Percentage (%) of 
children with AIDS, 
on ART 
40.6 64.9 68.4 78.6 94.4 94.8 95.6 96.1 
Footnotes 
AIDS: Acquired Immunodeficiency Syndrome 
ART: Antiretroviral Therapy 
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Appendix 2: Data extraction form 
 
a. Date of admission 
b. Patient identification number 
c. Age 
d. Gender 
e. HIV status 
f. Date of HIV result 
g. CD4+ count (absolute count and percentage) 
i. Date of CD4+ count 
h. HIV viral load (RNA copies per milliliter and log values) 
i. Date of viral load 
j. TB result 
i. Smear microscopy 
ii. Culture 
iii. Susceptibility 
     iv. Date of TB result 
k. TB specimen type: gastric aspirate, expectorated sputum, induced sputum 
or broncho-alveolar lavage 
l. Nutritional assessment  
i. Weight on admission (kg) 
ii. Length on admission (cm) 
iii. Oedema (Yes/No) 
m. Discharge Diagnosis 
n. ART status (for HIV-infected children) 
i. On ART: Yes/No 
ii. ART Regimen used 
iii. Date of initiation of ART 
o. Blood culture result 
i. Date of blood culture 
p. Nasopharyngeal swab result 
i. Date of nasopharyngeal swab 
q. TB Classification: Confirmed/Probable/Possible  
r. Patient outcome: discharged/died 
i. Date of patient outcome 
s. Started on TB treatment before discharge from hospital? Yes/No
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Appendix 3: WHO immunological classification for established HIV infection 
(CD4% or absolute number per mm3) (43) 
 
 Not significant Mild  Advanced Severe 
<11 months >35%  30-35% 25-29% <25% 
12-35 months >30% 25-30% 20-24% <20% 
36-59 months >25%  20-25% 15-19% <15% 
>5yrs >500  350-499 200-349 <200/<15%  
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Appendix 4: Population denominators and HIV prevalence by age-group in 
Soweto, South Africa for years 2005 to 2012 
PCV Vaccination Era Year Age Total population
1
 HIV 
prevalence
2
 
Pre-PCV 2005 <12 months 23640 6.00% 
  12-23 months 24154 3.67% 
  24-59 months 72490 3.67% 
  60-119 months 115649 1.66% 
  120-167 months 101335 0.18% 
     
Pre-PCV 2006 <12 months 22382 5.68% 
  12-23 months 23526 3.91% 
  24-59 months 73271 3.91% 
  60-119 months 120787 2.04% 
  120-167 months 104776 0.30% 
     
Pre-PCV 2007 <12 months 21326 5.24% 
  12-23 months 22830 4.09% 
  24-59 months 72977 4.09% 
  60-119 months 124359 2.42% 
  120-167 months 109994 0.47% 
     
Pre-PCV 2008 <12 months 21077 4.63% 
  12-23 months 22578 4.14% 
  24-59 months 72620 4.14% 
  60-119 months 126511 2.75% 
  120-167 months 115290 0.70% 
     
Transitional PCV 2009 <12 months 21627 4,04% 
  12-23 months 22794 4,15% 
  24-59 months 72358 4,15% 
  60-119 months 127464 3,06% 
  120-167 months 120454 0,97% 
     
Transitional PCV 2010 <12 months 22660 3,94% 
  12-23 months 23342 3,95% 
  24-59 months 72431 3,95% 
  60-119 months 127835 3,30% 
  120-167 months 124897 1,29% 
     
Established PCV 2011 <12 months 23777 3.89% 
  12-23 months 24009 3.68% 
  24-59 months 72878 3.68% 
  60-119 months 128204 3.48% 
  120-167 months 128423 1.62% 
     
Established PCV 2012 <12 months 24083 3.83% 
  12-23 months 24113 3.47% 
  24-59 months 72568 3.47% 
  60-119 months 128196 3.53% 
  120-167 months 131551 1.95% 
1The population estimates for region D, Soweto (Johannesburg) as per Statistics South Africa  
2HIV prevalence in the study population from the AIDS and Demographic models 2008 as per 
the Actuarial Society of South Africa 
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Appendix 5: Ethics Clearance Certificate 
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